ClinicalTrials.gg
CompletedNCT02162199Updated Oct 23, 2014

A Single Dose Study of Debio 1450 in Healthy Subjects

A Phase 1 interventional study of Debio 1450 and Placebo in Bacterial Infections, sponsored by Debiopharm International SA. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-23.

Sponsored by Debiopharm International SA (part of Debiopharm) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 181 studies in Bacterial Infections with a site in United States — 12 open to participants now, 15 under way, 2 of them phase 3. Bacterial Infections · United States.

Enrollment
89th of 151
48 · median 62
Started
2014
with 11 others
Phase 1
66 of 181
2 open now
Registered
82nd of 181
by date
Lead sponsor
3 of 181
Debiopharm International SA

Among the 181 studies in Bacterial Infections with a site in United States, this one is the 89th largest by enrollment of the 151 interventional ones that give a count, is one of 12 that started in 2014, is one of 66 in phase 1, and was the 82nd registered.

Bacterial Infections

585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.

Browse Bacterial Infections studies →

Open to participants now

12 of the 181 studies in Bacterial Infections with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 181 studies in Bacterial Infections with a site in United States, or all of them as a file.
02

Study summary

The sponsor is trying to develop a medicine for infections that are not cured by regular antibiotics. They have an experimental drug called Debio 1450 that may work. They need about 48 healthy adults to volunteer for this study.

This study looks at what the body does to the drug. It measures how the amount of drug in blood and urine changes over time.

From the screening visit through the follow-up visit may be up to 40 days. Volunteers go to the clinic in Baltimore for a screening visit. The study doctor chooses qualified volunteers to participate or serve as alternates. Alternates might not actually complete the study procedures.

The study doctor divides participants into groups of eight. Six receive Debio 1450 and 2 receive Placebo. The drug each participant receives is decided by chance - like flipping a coin.

Eligible volunteers check into the clinic for testing and those chosen to participate remain for a 5-day/ 4-night stay. The clinic serves standard meals, except when fasting is required. Participants must stay at the clinic for the length of the study.

This study is a "dose escalation" study. That means that if no safety concerns come up a new group starts. Each new group of eight participants receives more capsules.

The study product is contained in capsules. Each capsule contains either placebo or 40 mg Debio 1450. After fasting overnight, the first two participants in the group receive their capsules. One gets Debio 1450 and one gets Placebo. If these participants tolerate side effects for 24 hours, the remaining six participants receive their assigned capsules.

The plan is to increase the dose for the next group. The study doctor reviews the measurements collected from each group after three days. He may decide to repeat, increase, or lower the dose or even stop the study. The most any participant receives is 800 mg in 20 capsules.

03

Conditions studied

  • Bacterial Infections

Browse trials for

Keywords

  • Antibiotic
  • Antibiotic Resistant Bacterial Infection
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is a healthy adult
  2. Has met protocol-specified criteria for qualification and use of
  3. Is willing and able to remain confined in the study unit for the entire duration of the treatment period and comply with restrictions related to food, drink and medications
  4. Has voluntarily consented to participate and provided written prior to any protocol-specific procedures

Exclusion criteria

Exclusion Criteria:

  1. Has screening laboratory values outside protocol-specified limits
  2. Has history of a allergic drug reaction
  3. Has donated a volume of plasma or whole blood within a time frame not allowed per protocol
  4. Has historical or current use not allowed per protocol of:

    1. over-the-counter medications
    2. certain foods; dietary, mineral or herbal supplements
    3. licit or illicit drugs (including experimental drugs, caffeine, nicotine and alcohol)
  5. Has signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise:

    1. the safety or well-being of the participant or study staff
    2. the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding)
    3. the analysis of results
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Debio 1450

    Debio 1450 40 mg, capsules, orally, once in the morning under fasted conditions

    Drug: Debio 1450

  • Placebo comparator
    Placebo

    Placebo 0 mg, matching capsules, orally, once in the morning under fasted conditions

    Drug: Placebo

Interventions

  • Single sentinel dosing of 40 mg per unit capsules is planned to escalate from 80 mg to 160, 320, 480, 640 and 800 mg, per respective dosing group. Doses may be modified based on review of available safety and pharmacokinetic (PK) data.

  • DrugPlacebo

    Matching single sentinel dosing of placebo capsules is planned to escalate from 2 capsules to 4, 8, 12, 16 and 20 capsules, per respective dosing group. The number of capsules will match those delivering Debio 1450 for the group, as those doses may be modified based on review of available safety and pharmacokinetic (PK) data.

06

What researchers measure

Primary outcomes

  1. Number of participants with at least one treatment emergent adverse event (TEAE)

    Time frame: within 10 days post-dose

  2. Maximum observed plasma concentration (Cmax) of Debio 1450

    Time frame: within 60 hours post-dose

  3. Time of maximum observed plasma concentration (tmax) of Debio 1450

    Time frame: within 60 hours post-dose

Secondary outcomes

  1. Area under the plasma concentration-time curve (AUC) of Debio 1450

    Categorical results will include from time zero to 24 hours post-dose (AUC0-24), from time zero to the last measured concentration (AUC0-t), and from time zero extrapolated to infinity (AUC0-∞).

    Time frame: pre-dose, 15, 30 and 60 minutes post-dose, and 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 30, 36, 48 and 60 hours post-dose

  2. Percentage of AUC0-∞ that is due to extrapolation beyond the last quantifiable concentration measurement (%AUCex) of Debio 1450

    Time frame: pre-dose, 15, 30 and 60 minutes post-dose, and 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 30, 36, 48 and 60 hours post-dose

  3. Elimination half-life (t½) of Debio 1450

    Time frame: pre-dose, 15, 30 and 60 minutes post-dose, and 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 30, 36, 48 and 60 hours post-dose

  4. Terminal elimination rate constant (λz) of Debio 1450

    Time frame: pre-dose, 15, 30 and 60 minutes post-dose, and 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 30, 36, 48 and 60 hours post-dose

  5. Mean residence time (MRT) of Debio 1450

    Time frame: pre-dose, 15, 30 and 60 minutes post-dose, and 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 30, 36, 48 and 60 hours post-dose

  6. Apparent clearance following oral administration (CL/F) of Debio 1450

    Time frame: pre-dose, 15, 30 and 60 minutes post-dose, and 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 30, 36, 48 and 60 hours post-dose

  7. Apparent volume of distribution of Debio 1450 during terminal phase (Vz/F)

    Time frame: pre-dose, 15, 30 and 60 minutes post-dose, and 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 30, 36, 48 and 60 hours post-dose

  8. Cumulative amount of unchanged Debio 1450 excreted in urine (Ae)

    Time frame: pre-dose and 0-2, 2-6, 6-12, 12-24, 24-48 and 48-60 hours post-dose

  9. Percentage of cumulative amount of unchanged Debio 1450 excreted in urine (Ae%)

    Time frame: pre-dose and 0-2, 2-6, 6-12, 12-24, 24-48 and 48-60 hours post-dose

  10. Renal clearance following oral administration

    Time frame: pre-dose and 0-2, 2-6, 6-12, 12-24, 24-48 and 48-60 hours post-dose

  11. Number of participants with clinically significant change from baseline in vital signs

    Time frame: within 10 days post-dose

  12. Number of participants with clinically significant change from baseline in 12-lead electrocardiogram (ECG) parameters

    Time frame: within 48 hours post-dose

  13. Number of participants with clinically significant change from baseline in clinical laboratory parameters

    Time frame: within 51 hours post-dose

07

Study locations

1 site
  • Early Phase Clinical Unit
    Baltimore, Maryland 21225, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2014, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2014
First posted
Jun 12, 2014
Start
Jun 2014
Primary completionActual
Oct 2014
CompletionActual
Oct 2014
Last update
Oct 23, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02162199
Responsible party
Sponsor
First posted
Jun 12, 2014
Start date
Jun 2014
Primary completion
Oct 2014
Completion
Oct 2014
Last update
Oct 23, 2014

Study contacts

Azra Hussaini, MD
principal investigator · Early Phase Clinical Unit - Baltimore, USA

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Afabicin

Start the discussion